Product Details
Dupixent
Dupilumab200 mg/1.14 mL (175 mg/mL)
Solution for Subcutaneous Injection
Single-Use 1.14-mL Pre-Filled Syringe (Preservative-Free)
DIN/PIN/NPN
02492504
Manufacturer
Sanofi Genzyme, a Division of Sanofi-Aventis Canada Inc.
Formulary Listing Date
2021-05-06
Unit Price
978.7000
Amount MOH Pays
978.7000
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
D11AH05
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Asthma | Dupilumab
Initiation Criteria: For the treatment of severe asthma in patients meeting the following criteria:
1Patients with type 2 or eosinophilic phenotypes are considered to be inadequately controlled if they have worsening of asthma resulting in administration of systemic corticosteroids for at least 3 days, or an emergency room visit, or hospitalization, in the past 12 months Renewal criteria: Renewals will be considered on a case-by-case basis for patients 6 years of age or older with type 2 or eosinophilic asthma who do not meet any of the following discontinuation/stopping criteria:
Renewals will be considered on a case-by-case basis for patients 12 years of age or older on maintenance treatment with OCS dependent asthma who do not meet any of the following stopping criteria:
Approval duration of initial and renewals: 1 year EAP Drug Request Form: |
Dermatology Drugs | Dupilumab
Initiation Criteria: For the treatment of moderate to severe atopic dermatitis in patients meeting the all the following criteria:
Exclusion Criteria: Dupilumab will not be funded if it is used in combination with phototherapy or any immunomodulatory drugs (including biologics (Note 3) or a Janus kinase [JAK] inhibitor treatment) for treatment of AD. Notes:
Renewal Criteria: First renewal: Subsequent renewals: Duration of Approval for initial requests: 6 months Duration of Approval for first and second renewal: 6 months Duration of Approval for 3rd and subsequent renewals: 1 year Recommended dose: Adults: An initial dose of 600 mg followed by 300 mg every other week. Refer to the product monograph for dosing in adolescents 17 years of age and younger. EAP Drug Request Form: |